



March 10, 2025

Dear University of Arkansas System Member,

MedImpact Healthcare Systems, Inc. (“MedImpact”), on behalf of the University of Arkansas System Health Plan (the “University”), will be implementing changes to the prescription benefit plan that affects you. **Please continue to read this entire letter.**

Effective July 1, 2025, your prescription benefit plan will no longer allow the concurrent use of drugs designated as SGLT2 (sodium-glucose co-transporter 2) inhibitors and GLP1 (glucagon-like peptide-1) receptor agonists. **You are receiving this letter because our records indicate you had prescriptions filled for (Farxiga, Synjardy, Xigduo XR, Jardiance) and (Ozempic, Trulicity, Liraglutide) concurrently within the last 120 days.**

If your doctor determines that concurrent use of the formulary covered medications are necessary for your therapy due to your medical condition, an appeal process for coverage of a medication is available. To request coverage, your doctor must submit the appeal form and required medical documentation to EBRx by fax to 1-877-540-9036.

Pharmacy benefits are subject to terms, conditions and eligibility as outlined in the benefit documentation in effect at the time services are provided. The above change to your prescription benefit plan is directed by the University’s Pharmacy Advisory Committee.

For questions, please contact MedImpact at 1-800-788-2949.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

The University of Arkansas System’s’ prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System’s Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.